15 results on '"Gu, Xiaoying"'
Search Results
2. In-hospital complications associated with COVID-19.
- Author
-
Gu, Xiaoying and Cao, Bin
- Subjects
- *
COVID-19 - Published
- 2021
- Full Text
- View/download PDF
3. Long-term effects on survivors with COVID-19 – Authors' reply.
- Author
-
Huang, Lixue, Gu, Xiaoying, and Cao, Bin
- Subjects
- *
COVID-19 , *AUTHORS - Published
- 2021
- Full Text
- View/download PDF
4. Long-term effects of COVID-19 on kidney function - Authors' reply.
- Author
-
Huang, Lixue, Gu, Xiaoying, Wang, Yeming, Huang, Chaolin, and Cao, Bin
- Subjects
- *
COVID-19 , *KIDNEY physiology - Published
- 2021
- Full Text
- View/download PDF
5. Full spectrum of COVID-19 severity still being depicted - Authors' reply.
- Author
-
Gu, Xiaoying, Cao, Bin, and Wang, Jianwei
- Subjects
- *
SARS virus , *COVID-19 , *EPIDEMICS , *SEVERITY of illness index - Abstract
Full spectrum of COVID-19 severity still being depicted - Authors' reply Zhou Xu and colleagues point out that mortality, which should be referred correctly and more clearly as case fatality ratio, among the first 41 cases with laboratory-confirmed 2019 novel coronavirus disease (COVID-19; previously known as 2019-nCoV) was misleading in our Article.[1] We definitely agree that the case fatality ratio among the first 41 cases cannot represent the case fatality ratio of the full disease spectrum during the outbreak of COVID-19. From the perspective of treatment, even the most up-to-date case fatality ratio is expected to decrease as diagnosis and treatment procedure for patients with pneumonia who are infected with SARS-CoV-2 is improving,[3] potential drugs to treat COVID-19 are being evaluated for efficacy and safety in ongoing clinical trials,[[4]] and management is becoming more intense, not only for patients with severe infection but also for those with moderate, mild, or even asymptomatic infection. [Extracted from the article]
- Published
- 2020
- Full Text
- View/download PDF
6. 1-year outcomes in hospital survivors with COVID-19: a longitudinal cohort study.
- Author
-
Huang, Lixue, Yao, Qun, Gu, Xiaoying, Wang, Qiongya, Ren, Lili, Wang, Yeming, Hu, Ping, Guo, Li, Liu, Min, Xu, Jiuyang, Zhang, Xueyang, Qu, Yali, Fan, Yanqing, Li, Xia, Li, Caihong, Yu, Ting, Xia, Jiaan, Wei, Ming, Chen, Li, and Li, Yanping
- Subjects
- *
COVID-19 , *RESEARCH & development , *PULMONARY function tests , *MEDICAL sciences , *LONGITUDINAL method , *MEDICAL research - Abstract
Background: The full range of long-term health consequences of COVID-19 in patients who are discharged from hospital is largely unclear. The aim of our study was to comprehensively compare consequences between 6 months and 12 months after symptom onset among hospital survivors with COVID-19.Methods: We undertook an ambidirectional cohort study of COVID-19 survivors who had been discharged from Jin Yin-tan Hospital (Wuhan, China) between Jan 7 and May 29, 2020. At 6-month and 12-month follow-up visit, survivors were interviewed with questionnaires on symptoms and health-related quality of life (HRQoL), and received a physical examination, a 6-min walking test, and laboratory tests. They were required to report their health-care use after discharge and work status at the 12-month visit. Survivors who had completed pulmonary function tests or had lung radiographic abnormality at 6 months were given the corresponding tests at 12 months. Non-COVID-19 participants (controls) matched for age, sex, and comorbidities were interviewed and completed questionnaires to assess prevalent symptoms and HRQoL. The primary outcomes were symptoms, modified British Medical Research Council (mMRC) score, HRQoL, and distance walked in 6 min (6MWD). Multivariable adjusted logistic regression models were used to evaluate the risk factors of 12-month outcomes.Findings: 1276 COVID-19 survivors completed both visits. The median age of patients was 59·0 years (IQR 49·0-67·0) and 681 (53%) were men. The median follow-up time was 185·0 days (IQR 175·0-198·0) for the 6-month visit and 349·0 days (337·0-361·0) for the 12-month visit after symptom onset. The proportion of patients with at least one sequelae symptom decreased from 68% (831/1227) at 6 months to 49% (620/1272) at 12 months (p<0·0001). The proportion of patients with dyspnoea, characterised by mMRC score of 1 or more, slightly increased from 26% (313/1185) at 6-month visit to 30% (380/1271) at 12-month visit (p=0·014). Additionally, more patients had anxiety or depression at 12-month visit (26% [331/1271] at 12-month visit vs 23% [274/1187] at 6-month visit; p=0·015). No significant difference on 6MWD was observed between 6 months and 12 months. 88% (422/479) of patients who were employed before COVID-19 had returned to their original work at 12 months. Compared with men, women had an odds ratio of 1·43 (95% CI 1·04-1·96) for fatigue or muscle weakness, 2·00 (1·48-2·69) for anxiety or depression, and 2·97 (1·50-5·88) for diffusion impairment. Matched COVID-19 survivors at 12 months had more problems with mobility, pain or discomfort, and anxiety or depression, and had more prevalent symptoms than did controls.Interpretation: Most COVID-19 survivors had a good physical and functional recovery during 1-year follow-up, and had returned to their original work and life. The health status in our cohort of COVID-19 survivors at 12 months was still lower than that in the control population.Funding: Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences, the National Natural Science Foundation of China, the National Key Research and Development Program of China, Major Projects of National Science and Technology on New Drug Creation and Development of Pulmonary Tuberculosis, the China Evergrande Group, Jack Ma Foundation, Sino Biopharmaceutical, Ping An Insurance (Group), and New Sunshine Charity Foundation. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
7. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study.
- Author
-
Huang, Chaolin, Huang, Lixue, Wang, Yeming, Li, Xia, Ren, Lili, Gu, Xiaoying, Kang, Liang, Guo, Li, Liu, Min, Zhou, Xing, Luo, Jianfeng, Huang, Zhenghui, Tu, Shengjin, Zhao, Yue, Chen, Li, Xu, Decui, Li, Yanping, Li, Caihong, Peng, Lu, and Li, Yong
- Subjects
- *
HOSPITAL admission & discharge , *COVID-19 , *RESEARCH & development , *MEDICAL sciences , *PATIENT readmissions , *DRUG development , *FIBROMYALGIA , *POSTPOLIOMYELITIS syndrome - Abstract
The long-term health consequences of COVID-19 remain largely unclear. The aim of this study was to describe the long-term health consequences of patients with COVID-19 who have been discharged from hospital and investigate the associated risk factors, in particular disease severity. We did an ambidirectional cohort study of patients with confirmed COVID-19 who had been discharged from Jin Yin-tan Hospital (Wuhan, China) between Jan 7 and May 29, 2020. Patients who died before follow-up; patients for whom follow-up would be difficult because of psychotic disorders, dementia, or readmission to hospital; those who were unable to move freely due to concomitant osteoarthropathy or immobile before or after discharge due to diseases such as stroke or pulmonary embolism; those who declined to participate; those who could not be contacted; and those living outside of Wuhan or in nursing or welfare homes were all excluded. All patients were interviewed with a series of questionnaires for evaluation of symptoms and health-related quality of life, underwent physical examinations and a 6-min walking test, and received blood tests. A stratified sampling procedure was used to sample patients according to their highest seven-category scale during their hospital stay as 3, 4, and 5–6, to receive pulmonary function test, high resolution CT of the chest, and ultrasonography. Enrolled patients who had participated in the Lopinavir Trial for Suppression of SARS-CoV-2 in China received SARS-CoV-2 antibody tests. Multivariable adjusted linear or logistic regression models were used to evaluate the association between disease severity and long-term health consequences. In total, 1733 of 2469 discharged patients with COVID-19 were enrolled after 736 were excluded. Patients had a median age of 57·0 years (IQR 47·0–65·0) and 897 (52%) were male and 836 (48%) were female. The follow-up study was done from June 16 to Sept 3, 2020, and the median follow-up time after symptom onset was 186·0 days (175·0–199·0). Fatigue or muscle weakness (52%, 855 of 1654) and sleep difficulties (26%, 437 of 1655) were the most common symptoms. Anxiety or depression was reported among 23% (367 of 1616) of patients. The proportions of 6-min walking distance less than the lower limit of the normal range were 17% for those at severity scale 3, 13% for severity scale 4, and 28% for severity scale 5–6. The corresponding proportions of patients with diffusion impairment were 22% for severity scale 3, 29% for scale 4, and 56% for scale 5–6, and median CT scores were 3·0 (IQR 2·0–5·0) for severity scale 3, 4·0 (3·0–5·0) for scale 4, and 5·0 (4·0–6·0) for scale 5–6. After multivariable adjustment, patients showed an odds ratio (OR) of 1·61 (95% CI 0·80–3·25) for scale 4 versus scale 3 and 4·60 (1·85–11·48) for scale 5–6 versus scale 3 for diffusion impairment; OR 0·88 (0·66–1·17) for scale 4 versus scale 3 and OR 1·76 (1·05–2·96) for scale 5–6 versus scale 3 for anxiety or depression, and OR 0·87 (0·68–1·11) for scale 4 versus scale 3 and 2·75 (1·61–4·69) for scale 5–6 versus scale 3 for fatigue or muscle weakness. Of 94 patients with blood antibodies tested at follow-up, the seropositivity (96·2% vs 58·5%) and median titres (19·0 vs 10·0) of the neutralising antibodies were significantly lower compared with at the acute phase. 107 of 822 participants without acute kidney injury and with an estimated glomerular filtration rate (eGFR) of 90 mL/min per 1·73 m2 or more at acute phase had eGFR less than 90 mL/min per 1·73 m2 at follow-up. At 6 months after acute infection, COVID-19 survivors were mainly troubled with fatigue or muscle weakness, sleep difficulties, and anxiety or depression. Patients who were more severely ill during their hospital stay had more severe impaired pulmonary diffusion capacities and abnormal chest imaging manifestations, and are the main target population for intervention of long-term recovery. National Natural Science Foundation of China, Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences, National Key Research and Development Program of China, Major Projects of National Science and Technology on New Drug Creation and Development of Pulmonary Tuberculosis, and Peking Union Medical College Foundation. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
8. Rheumatic Symptoms Following Coronavirus Disease 2019 (COVID-19): A Chronic Post–COVID-19 Condition.
- Author
-
Cui, Dan, Wang, Yeming, Huang, Lixue, Gu, Xiaoying, Huang, Zhisheng, Mu, Shengrui, Wang, Chen, and Cao, Bin
- Subjects
- *
COVID-19 , *KNEE joint , *JOINT pain , *CHRONIC diseases , *JOINT diseases , *CORONAVIRUS diseases - Abstract
Background Detailed characteristics of rheumatic symptoms of coronavirus disease 2019 (COVID-19) were still unknown. We aim to investigate the proportions, characteristics, and risk factors of this condition. Methods In this prospective, longitudinal cohort study, discharged patients with COVID-19 were interviewed face-to-face at 12 months after symptom onset. Rheumatic symptoms following COVID-19 included newly occurring joint pain and/or joint swelling. The risk factors of developing rheumatic symptoms were identified by multivariable logistic regression analysis. Results In total, 1296 of 2469 discharged patients with COVID-19 were enrolled in this study. Among them, 160 (12.3% [95% confidence interval {CI}, 10.6%–14.3%]) suffered from rheumatic symptoms following COVID-19 at 12-month follow-up. The most frequently involved joints were the knee joints (38%), followed by hand (25%) and shoulder (19%). Rheumatic symptoms were independent of the severity of illness and corticosteroid treatment during the acute phase, while elderly age (odds ratio [OR], 1.22 [95% CI, 1.06–1.40]) and female sex (OR, 1.58 [95% CI, 1.12–2.23]) were identified as the risk factors for this condition. Conclusions Our investigation showed a considerable proportion of rheumatic symptoms following COVID-19 in discharged patients, which highlights the need for continuing attention. Notably, rheumatic symptoms following COVID-19 were independent of the severity of illness and corticosteroid treatment during the acute phase. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
9. COVID‐19 diagnosis on CT scan images using a generative adversarial network and concatenated feature pyramid network with an attention mechanism.
- Author
-
Li, Zonggui, Zhang, Junhua, Li, Bo, Gu, Xiaoying, and Luo, Xudong
- Subjects
- *
GENERATIVE adversarial networks , *COVID-19 , *COMPUTED tomography , *COVID-19 testing , *DEEP learning , *DATA augmentation - Abstract
Objective: Coronavirus disease 2019 (COVID‐19) has caused hundreds of thousands of infections and deaths. Efficient diagnostic methods could help curb its global spread. The purpose of this study was to develop and evaluate a method for accurately diagnosing COVID‐19 based on computed tomography (CT) scans in real time. Methods: We propose an architecture named "concatenated feature pyramid network" ("Concat‐FPN") with an attention mechanism, by concatenating feature maps of multiple. The proposed architecture is then used to form two networks, which we call COVID‐CT‐GAN and COVID‐CT‐DenseNet, the former for data augmentation and the latter for data classification. Results: The proposed method is evaluated on 3 different numbers of magnitude of COVID‐19 CT datasets. Compared with the method without GANs for data augmentation or the original network auxiliary classifier generative adversarial network, COVID‐CT‐GAN increases the accuracy by 2% to 3%, the recall by 2% to 4%, the precision by 1% to 3%, the F1‐score by 1% to 3%, and the area under the curve by 1% to 4%. Compared with the original network DenseNet‐201, COVID‐CT‐DenseNet increases the accuracy by 1% to 3%, the recall by 4% to 9%, the precision by 1%, the F1‐score by 1% to 3%, and the area under the curve by 2%. Conclusion: The experimental results show that our method improves the efficiency of diagnosing COVID‐19 on CT images, and helps overcome the problem of limited training data when using deep learning methods to diagnose COVID‐19. Significance: Our method can help clinicians build deep learning models using their private datasets to achieve automatic diagnosis of COVID‐19 with a high precision. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
10. The Effect of Prior Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Treatment on Coronavirus Disease 2019 (COVID-19) Susceptibility and Outcome: A Systematic Review and Meta-analysis.
- Author
-
Xu, Jiuyang, Teng, Yaqun, Shang, Lianhan, Gu, Xiaoying, Fan, Guohui, Chen, Yijun, Tian, Ran, Zhang, Shuyang, and Cao, Bin
- Subjects
- *
COVID-19 , *META-analysis , *CONFIDENCE intervals , *SYSTEMATIC reviews , *ACE inhibitors , *SEVERITY of illness index , *RISK assessment , *TREATMENT effectiveness , *DISEASE susceptibility , *ANGIOTENSIN receptors - Abstract
There have been arguments on whether angiotensin-converting enzyme inhibitor (ACEI) and angiotensin receptor blocker (ARB) treatment alters the risk of coronavirus disease 2019 (COVID-19) susceptibility and disease severity. We identified a total of 102 eligible studies for systematic review, in which 49 studies adjusting for confounders were included in the meta-analysis. We found no association between prior ACEI/ARB use and risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in the general population (adjusted odds ratio [aOR], 1.00; 95% confidence interval [CI],.94–1.05). The risk of mortality (aOR,.87; 95% CI,.66–1.04) and severe outcomes (aOR,.95; 95% CI,.73–1.24) were also unchanged among COVID-19 patients taking ACEIs/ARBs. These findings remained consistent in subgroup analyses stratified by populations, drug exposures, and other secondary outcomes. This systematic review provides evidence-based support to current medical guidelines and position statements that ACEIs/ARBs should not be discontinued. Additionally, there has been no evidence for initiating ACEI/ARB regimen as prevention or treatment of COVID-19. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
11. Antibody Responses and Clinical Outcomes in Adults Hospitalized With Severe Coronavirus Disease 2019 (COVID-19): A Post hoc Analysis of LOTUS China Trial.
- Author
-
Ren, Lili, Fan, Guohui, Wu, Wenjuan, Guo, Li, Wang, Yeming, Li, Xia, Wang, Conghui, Gu, Xiaoying, Li, Caihong, Wang, Ying, Wang, Geng, Zhou, Fei, Liu, Zhibo, Ge, Qing, Zhang, Yi, Li, Hui, Zhang, Lulu, Xu, Jiuyang, Wang, Chen, and Wang, Jianwei
- Subjects
- *
REVERSE transcriptase polymerase chain reaction , *STATISTICS , *COVID-19 , *IMMUNOGLOBULINS , *VIRAL load , *TREATMENT effectiveness , *HOSPITAL care , *ENZYME-linked immunosorbent assay , *VIRAL antibodies , *POLYMERASE chain reaction , *DATA analysis - Abstract
Background The characteristics of neutralizing antibodies (NAbs) and antibody against major antigen proteins related to clinical outcomes in severe coronavirus disease 2019 (COVID-19) patients were still less known. Methods NAbs and antibodies targeting nucleocapsid (N), spike protein (S), and the receptor-binding domain (RBD) in longitudinal plasma samples from the LOTUS China trial were measured by microneutralization assay and enzyme-linked immunosorbent assay (ELISA). Viral load was determined by real-time reverse transcription polymerase chain reaction (RT-PCR). A total of 576 plasma and 576 throat swabs were collected from 191 COVID-19 patients. Antibody titers related to adverse outcome and clinical improvement were analyzed. Multivariable adjusted generalized linear mixed model for random effects were developed. Results After day 28 post symptoms onset, the rate of antibody positivity reached 100% for RBD-immunoglobulin M (IgM), 97.8% for S-IgM, 100% for N-immunoglobulin G (IgG), 100% for RBD-IgG, 91.1% for N-IgM, and 91.1% for NAbs. The NAbs titers increased over time in both survivors and nonsurvivors and correlated to IgG antibodies against N, S, and RBD, whereas its presence showed no statistical correlation with death. N-IgG (slope −2.11, 95% confidence interval [CI] −3.04 to −1.18, P <.0001), S-IgG (slope −2.44, 95% CI −3.35 to −1.54, P <.0001), and RBD-IgG (slope −1.43, 95% CI −1.98 to −.88, P <.0001) were negatively correlated with viral load. S-IgG titers were lower in nonsurvivors than survivors (P =.020) at week 4 after symptoms onset. Conclusions IgM and IgG against N, S, and RBD and NAbs developed in most severe COVID-19 patients and do not correlate clearly with clinical outcomes. The levels of IgG antibodies against N, S, and RBD were related to viral clearance. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
12. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study.
- Author
-
Huang, Chaolin, Huang, Lixue, Wang, Yeming, Li, Xia, Ren, Lili, Gu, Xiaoying, Kang, Liang, Guo, Li, Liu, Min, Zhou, Xing, Luo, Jianfeng, Huang, Zhenghui, Tu, Shengjin, Zhao, Yue, Chen, Li, Xu, Decui, Li, Yanping, Li, Caihong, Peng, Lu, and Li, Yong
- Subjects
- *
HOSPITAL admission & discharge , *COVID-19 , *COVID-19 testing , *MEDICAL sciences , *POSTPOLIOMYELITIS syndrome , *DRUG development , *Q fever , *PSYCHOLOGICAL manifestations of general diseases - Abstract
Background: The long-term health consequences of COVID-19 remain largely unclear. The aim of this study was to describe the long-term health consequences of patients with COVID-19 who have been discharged from hospital and investigate the associated risk factors, in particular disease severity.Methods: We did an ambidirectional cohort study of patients with confirmed COVID-19 who had been discharged from Jin Yin-tan Hospital (Wuhan, China) between Jan 7, 2020, and May 29, 2020. Patients who died before follow-up, patients for whom follow-up would be difficult because of psychotic disorders, dementia, or re-admission to hospital, those who were unable to move freely due to concomitant osteoarthropathy or immobile before or after discharge due to diseases such as stroke or pulmonary embolism, those who declined to participate, those who could not be contacted, and those living outside of Wuhan or in nursing or welfare homes were all excluded. All patients were interviewed with a series of questionnaires for evaluation of symptoms and health-related quality of life, underwent physical examinations and a 6-min walking test, and received blood tests. A stratified sampling procedure was used to sample patients according to their highest seven-category scale during their hospital stay as 3, 4, and 5-6, to receive pulmonary function test, high resolution CT of the chest, and ultrasonography. Enrolled patients who had participated in the Lopinavir Trial for Suppression of SARS-CoV-2 in China received severe acute respiratory syndrome coronavirus 2 antibody tests. Multivariable adjusted linear or logistic regression models were used to evaluate the association between disease severity and long-term health consequences.Findings: In total, 1733 of 2469 discharged patients with COVID-19 were enrolled after 736 were excluded. Patients had a median age of 57·0 (IQR 47·0-65·0) years and 897 (52%) were men. The follow-up study was done from June 16, to Sept 3, 2020, and the median follow-up time after symptom onset was 186·0 (175·0-199·0) days. Fatigue or muscle weakness (63%, 1038 of 1655) and sleep difficulties (26%, 437 of 1655) were the most common symptoms. Anxiety or depression was reported among 23% (367 of 1617) of patients. The proportions of median 6-min walking distance less than the lower limit of the normal range were 24% for those at severity scale 3, 22% for severity scale 4, and 29% for severity scale 5-6. The corresponding proportions of patients with diffusion impairment were 22% for severity scale 3, 29% for scale 4, and 56% for scale 5-6, and median CT scores were 3·0 (IQR 2·0-5·0) for severity scale 3, 4·0 (3·0-5·0) for scale 4, and 5·0 (4·0-6·0) for scale 5-6. After multivariable adjustment, patients showed an odds ratio (OR) 1·61 (95% CI 0·80-3·25) for scale 4 versus scale 3 and 4·60 (1·85-11·48) for scale 5-6 versus scale 3 for diffusion impairment; OR 0·88 (0·66-1·17) for scale 4 versus scale 3 and OR 1·77 (1·05-2·97) for scale 5-6 versus scale 3 for anxiety or depression, and OR 0·74 (0·58-0·96) for scale 4 versus scale 3 and 2·69 (1·46-4·96) for scale 5-6 versus scale 3 for fatigue or muscle weakness. Of 94 patients with blood antibodies tested at follow-up, the seropositivity (96·2% vs 58·5%) and median titres (19·0 vs 10·0) of the neutralising antibodies were significantly lower compared with at the acute phase. 107 of 822 participants without acute kidney injury and with estimated glomerular filtration rate (eGFR) 90 mL/min per 1·73 m2 or more at acute phase had eGFR less than 90 mL/min per 1·73 m2 at follow-up.Interpretation: At 6 months after acute infection, COVID-19 survivors were mainly troubled with fatigue or muscle weakness, sleep difficulties, and anxiety or depression. Patients who were more severely ill during their hospital stay had more severe impaired pulmonary diffusion capacities and abnormal chest imaging manifestations, and are the main target population for intervention of long-term recovery.Funding: National Natural Science Foundation of China, Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences, National Key Research and Development Program of China, Major Projects of National Science and Technology on New Drug Creation and Development of Pulmonary Tuberculosis, and Peking Union Medical College Foundation. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
13. Low-to-moderate dose corticosteroids treatment in hospitalized adults with COVID-19.
- Author
-
Liu, Zhibo, Li, Xia, Fan, Guohui, Zhou, Fei, Wang, Yeming, Huang, Lixue, Yu, Jiapei, Yang, Luning, Shang, Lianhan, Xie, Ke, Xu, Jiuyang, Huang, Zhisheng, Gu, Xiaoying, Li, Hui, Zhang, Yi, Wang, Yimin, Huang, Zhenghui, and Cao, Bin
- Subjects
- *
NASAL cannula , *COVID-19 , *CORONAVIRUS disease treatment , *CORTICOSTEROIDS , *PROPORTIONAL hazards models , *ARTIFICIAL respiration - Abstract
Use of corticosteroids is common in the treatment of coronavirus disease 2019, but clinical effectiveness is controversial. We aimed to investigate the association of corticosteroids therapy with clinical outcomes of hospitalized COVID-19 patients. In this single-centre, retrospective cohort study, adult patients with confirmed coronavirus disease 2019 and dead or discharged between 29 December 2019 and 15 February 2020 were studied; 1:1 propensity score matchings were performed between patients with or without corticosteroid treatment. A multivariable COX proportional hazards model was used to estimate the association between corticosteroid treatment and in-hospital mortality by taking corticosteroids as a time-varying covariate. Among 646 patients, the in-hospital death rate was higher in 158 patients with corticosteroid administration (72/158, 45.6% vs. 56/488, 11.5%, p < 0.0001). After propensity score matching analysis, no significant differences were observed in in-hospital death between patients with and without corticosteroid treatment (47/124, 37.9% vs. 47/124, 37.9%, p 1.000). When patients received corticosteroids before they required nasal high-flow oxygen therapy or mechanical ventilation, the in-hospital death rate was lower than that in patients who were not administered corticosteroids (17/86, 19.8% vs. 26/86, 30.2%, log rank p 0.0102), whereas the time from admission to clinical improvement was longer (13 (IQR 10–17) days vs. 10 (IQR 8–13) days; p < 0.001). Using the Cox proportional hazards regression model accounting for time varying exposures in matched pairs, corticosteroid therapy was not associated with mortality difference (HR 0.98, 95% CI 0.93–1.03, p 0.4694). Corticosteroids use in COVID-19 patients may not be associated with in-hospital mortality. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
14. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.
- Author
-
Zhou, Fei, Yu, Ting, Du, Ronghui, Fan, Guohui, Liu, Ying, Liu, Zhibo, Xiang, Jie, Wang, Yeming, Song, Bin, Gu, Xiaoying, Guan, Lulu, Wei, Yuan, Li, Hui, Wu, Xudong, Xu, Jiuyang, Tu, Shengjin, Zhang, Yi, Chen, Hua, and Cao, Bin
- Subjects
- *
COVID-19 , *AGE distribution , *CONFIDENCE intervals , *EPIDEMICS , *FISHER exact test , *LONGITUDINAL method , *MEDICAL cooperation , *MEDICAL records , *PROBABILITY theory , *RESEARCH , *RESEARCH funding , *COMORBIDITY , *LOGISTIC regression analysis , *RETROSPECTIVE studies , *DISEASE progression , *FIBRIN fibrinogen degradation products , *DESCRIPTIVE statistics , *HOSPITAL mortality , *LYMPHOCYTE count , *ACQUISITION of data methodology , *ODDS ratio , *MANN Whitney U Test - Abstract
Background: Since December, 2019, Wuhan, China, has experienced an outbreak of coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Epidemiological and clinical characteristics of patients with COVID-19 have been reported but risk factors for mortality and a detailed clinical course of illness, including viral shedding, have not been well described.Methods: In this retrospective, multicentre cohort study, we included all adult inpatients (≥18 years old) with laboratory-confirmed COVID-19 from Jinyintan Hospital and Wuhan Pulmonary Hospital (Wuhan, China) who had been discharged or had died by Jan 31, 2020. Demographic, clinical, treatment, and laboratory data, including serial samples for viral RNA detection, were extracted from electronic medical records and compared between survivors and non-survivors. We used univariable and multivariable logistic regression methods to explore the risk factors associated with in-hospital death.Findings: 191 patients (135 from Jinyintan Hospital and 56 from Wuhan Pulmonary Hospital) were included in this study, of whom 137 were discharged and 54 died in hospital. 91 (48%) patients had a comorbidity, with hypertension being the most common (58 [30%] patients), followed by diabetes (36 [19%] patients) and coronary heart disease (15 [8%] patients). Multivariable regression showed increasing odds of in-hospital death associated with older age (odds ratio 1·10, 95% CI 1·03-1·17, per year increase; p=0·0043), higher Sequential Organ Failure Assessment (SOFA) score (5·65, 2·61-12·23; p<0·0001), and d-dimer greater than 1 μg/mL (18·42, 2·64-128·55; p=0·0033) on admission. Median duration of viral shedding was 20·0 days (IQR 17·0-24·0) in survivors, but SARS-CoV-2 was detectable until death in non-survivors. The longest observed duration of viral shedding in survivors was 37 days.Interpretation: The potential risk factors of older age, high SOFA score, and d-dimer greater than 1 μg/mL could help clinicians to identify patients with poor prognosis at an early stage. Prolonged viral shedding provides the rationale for a strategy of isolation of infected patients and optimal antiviral interventions in the future.Funding: Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences; National Science Grant for Distinguished Young Scholars; National Key Research and Development Program of China; The Beijing Science and Technology Project; and Major Projects of National Science and Technology on New Drug Creation and Development. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
15. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.
- Author
-
Huang, Chaolin, Wang, Yeming, Li, Xingwang, Ren, Lili, Zhao, Jianping, Hu, Yi, Zhang, Li, Fan, Guohui, Xu, Jiuyang, Gu, Xiaoying, Cheng, Zhenshun, Yu, Ting, Xia, Jiaan, Wei, Yuan, Wu, Wenjuan, Xie, Xuelei, Yin, Wen, Li, Hui, Liu, Min, and Xiao, Yan
- Subjects
- *
SARS disease , *COVID-19 , *ADULT respiratory distress syndrome , *ELECTRONIC health records , *EMERGING infectious diseases , *MEDICAL sciences , *SEAFOOD markets , *CHEST X rays , *COMPARATIVE studies , *COMPUTED tomography , *COUGH , *DEMOGRAPHY , *FEVER , *HOSPITAL care , *INTENSIVE care units , *RESEARCH methodology , *MEDICAL cooperation , *MYALGIA , *PROGNOSIS , *RESEARCH , *TIME , *COMORBIDITY , *EVALUATION research - Abstract
Background: A recent cluster of pneumonia cases in Wuhan, China, was caused by a novel betacoronavirus, the 2019 novel coronavirus (2019-nCoV). We report the epidemiological, clinical, laboratory, and radiological characteristics and treatment and clinical outcomes of these patients.Methods: All patients with suspected 2019-nCoV were admitted to a designated hospital in Wuhan. We prospectively collected and analysed data on patients with laboratory-confirmed 2019-nCoV infection by real-time RT-PCR and next-generation sequencing. Data were obtained with standardised data collection forms shared by WHO and the International Severe Acute Respiratory and Emerging Infection Consortium from electronic medical records. Researchers also directly communicated with patients or their families to ascertain epidemiological and symptom data. Outcomes were also compared between patients who had been admitted to the intensive care unit (ICU) and those who had not.Findings: By Jan 2, 2020, 41 admitted hospital patients had been identified as having laboratory-confirmed 2019-nCoV infection. Most of the infected patients were men (30 [73%] of 41); less than half had underlying diseases (13 [32%]), including diabetes (eight [20%]), hypertension (six [15%]), and cardiovascular disease (six [15%]). Median age was 49·0 years (IQR 41·0-58·0). 27 (66%) of 41 patients had been exposed to Huanan seafood market. One family cluster was found. Common symptoms at onset of illness were fever (40 [98%] of 41 patients), cough (31 [76%]), and myalgia or fatigue (18 [44%]); less common symptoms were sputum production (11 [28%] of 39), headache (three [8%] of 38), haemoptysis (two [5%] of 39), and diarrhoea (one [3%] of 38). Dyspnoea developed in 22 (55%) of 40 patients (median time from illness onset to dyspnoea 8·0 days [IQR 5·0-13·0]). 26 (63%) of 41 patients had lymphopenia. All 41 patients had pneumonia with abnormal findings on chest CT. Complications included acute respiratory distress syndrome (12 [29%]), RNAaemia (six [15%]), acute cardiac injury (five [12%]) and secondary infection (four [10%]). 13 (32%) patients were admitted to an ICU and six (15%) died. Compared with non-ICU patients, ICU patients had higher plasma levels of IL2, IL7, IL10, GSCF, IP10, MCP1, MIP1A, and TNFα.Interpretation: The 2019-nCoV infection caused clusters of severe respiratory illness similar to severe acute respiratory syndrome coronavirus and was associated with ICU admission and high mortality. Major gaps in our knowledge of the origin, epidemiology, duration of human transmission, and clinical spectrum of disease need fulfilment by future studies.Funding: Ministry of Science and Technology, Chinese Academy of Medical Sciences, National Natural Science Foundation of China, and Beijing Municipal Science and Technology Commission. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.